Hadis Yousefzadeh1, Farahzad Jabbari Azad2, Mahnaz Banihashemi3, Maryam Rastin1, Mahmoud Mahmoudi1. 1. Immunology Research Center, BuAli Research Institute, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. 2. Allergy Research Center, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. 3. Cutaneous Leishmaniasis Research Center, Department of Dermatology, Mashhad University of Medical Sciences, Mashhad, Iran.
Abstract
INTRODUCTION: We evaluated the effectiveness of concomitant treatment with methotrexate (MTX) plus micronutrients in comparison with monotherapy with MTX only in psoriasis patients. Plasma levels of interleukin-1 beta (IL-1β) and tumor necrosis factor alpha (TNF-α) were also measured and their association with clinical severity was evaluated. METHODS:Thirty psoriasis patients 20 to 50 years old with a PASI score >; 10 were divided randomly into two groups. Both groups were given oral methotrexate (0.2-0.3 mg/kg/week) for 12 weeks. In addition, Group B received one tablet of micronutrient supplement daily. Disease severity was calculated using the psoriasis area and severity index (PASI) score before and after 12 weeks. Levels of IL-1β andTNF-α were measured using enzyme-linked immunosorbent assay (ELISA). RESULTS: We found that 13 (86.6%) patients in Group B and 8 (53.3%) patients in Group A attained a mild PASI score (≤ 10% body involvement). IL-1β and TNF-α levels were significantly decreased in favor of Group B (p < 0.05). There was a significant correlation between changes in both IL-1β and TNF-α levels and PASI score after the study (p < 0.05). CONCLUSION: The results obtained were positive, and therefore double-blind randomized trials with a larger sample size are highly suggested to confirm or reject these results.
RCT Entities:
INTRODUCTION: We evaluated the effectiveness of concomitant treatment with methotrexate (MTX) plus micronutrients in comparison with monotherapy with MTX only in psoriasispatients. Plasma levels of interleukin-1 beta (IL-1β) and tumor necrosis factor alpha (TNF-α) were also measured and their association with clinical severity was evaluated. METHODS: Thirty psoriasispatients 20 to 50 years old with a PASI score > 10 were divided randomly into two groups. Both groups were given oral methotrexate (0.2-0.3 mg/kg/week) for 12 weeks. In addition, Group B received one tablet of micronutrient supplement daily. Disease severity was calculated using the psoriasis area and severity index (PASI) score before and after 12 weeks. Levels of IL-1β and TNF-α were measured using enzyme-linked immunosorbent assay (ELISA). RESULTS: We found that 13 (86.6%) patients in Group B and 8 (53.3%) patients in Group A attained a mild PASI score (≤ 10% body involvement). IL-1β and TNF-α levels were significantly decreased in favor of Group B (p < 0.05). There was a significant correlation between changes in both IL-1β and TNF-α levels and PASI score after the study (p < 0.05). CONCLUSION: The results obtained were positive, and therefore double-blind randomized trials with a larger sample size are highly suggested to confirm or reject these results.
Authors: April W Armstrong; Cindy J Chambers; Emanual Maverakis; Michelle Y Cheng; Cory A Dunnick; Mary-Margaret Chren; Joel M Gelfand; David J Wong; Brittany M Gibbons; Caitlin M Gibbons; Josefina Torres; Andrea C Steel; Elizabeth A Wang; Caitlin M Clark; Sanminder Singh; Heather A Kornmehl; Reason Wilken; Aleksandra G Florek; Adam R Ford; Chelsea Ma; Nazanin Ehsani-Chimeh; Sucharita Boddu; Mayumi Fujita; Paulina M Young; Cesar Rivas-Sanchez; Brenda I Cornejo; Laura C Serna; Eric R Carlson; Christianne J Lane Journal: JAMA Netw Open Date: 2018-10-05